The global cell therapy manufacturing automation market was valued at $3.34 billion in 2025 and is projected to reach $12.94 billion by 2035, expanding at a compound annual growth rate (CAGR) of 14.55% from 2026 to 2035, according to SNS Insider. Automation is being adopted across cell manipulation, culture, media handling, quality control and filling to reduce manual intervention, contamination risk, variability and costs. North America held the largest regional share at approximately 38% in 2025, while Asia Pacific is forecast to grow fastest at about 16.28% annually. Hardware was the largest component, upstream processing the largest process segment, clinical applications the largest application category, T-Cells the leading cell type and pharmaceutical and biotechnology companies the largest end-user group. Software, quality control, commercial applications, Natural Killer (NK) Cells and Contract Manufacturing Organizations are the respective fastest-growing segments. The market covers automation hardware and software used in clinical and commercial production of T-Cell and NK-cell therapies by pharmaceutical and biotechnology companies and contract manufacturers. Closed systems, robotics, artificial intelligence, digital process control and modular platforms are supporting adoption, although high capital costs, facility adaptation, equipment integration and specialized labor remain challenges.